Related Experiment Video
Updated: Nov 5, 2025
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer
Zhefeng Li1, Linlin Yang2, Hongzhi Wang1
1Center for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, James Comprehensive Cancer Center, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
Abstract:
Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer death in the United States. The development of drug resistance to commonly used chemotherapeutics in non-small-cell lung cancer (NSCLC) poses significant health risks and there is a dire need to improve patient outcomes. In this study, we report the use of RNA nanotechnology to display ligand on exosome that was loaded with small interfering RNA (siRNA) for NSCLC regression in animal trials. Cholesterol was used to anchor the ligand targeting epidermal growth factor receptor on exosomes that were loaded with siRNA to silence the antiapoptotic factor survivin. The cytosolic delivery of siRNA overcame the problem of endosome trapping, leading to potent gene knockdown, chemotherapy sensitization, and tumor regression, thus achieving a favorable IC50 of 20 nmol/kg siRNA encapsulated by exosome particles in the in vivo gene knockdown assessment.
Insights
Researchers utilized RNA nanotechnology to create targeted exosomes loaded with siRNA, effectively reducing non-small cell lung cancer (NSCLC) in animal models by silencing survivin and enhancing chemotherapy sensitivity.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer death.
- Drug resistance to conventional chemotherapy in NSCLC necessitates novel therapeutic strategies.
- Exosomes offer potential as drug delivery vehicles for cancer treatment.
Purpose of the Study:
- To investigate the efficacy of RNA nanotechnology-based exosome delivery for NSCLC regression.
- To develop a targeted delivery system for small interfering RNA (siRNA) to silence key oncogenes in NSCLC.
- To overcome challenges in siRNA delivery, such as endosomal entrapment.
Main Methods:
- Engineered exosomes displaying targeting ligands (cholesterol-anchored) for epidermal growth factor receptor (EGFR).
- Exosomes were loaded with siRNA to silence the antiapoptotic gene, survivin.
- Evaluated the therapeutic effect in NSCLC animal models, assessing gene knockdown, chemotherapy sensitization, and tumor regression.
Main Results:
- Cholesterol-anchored ligands facilitated EGFR-targeted exosome delivery.
- Cytosolic siRNA delivery via exosomes effectively silenced survivin, overcoming endosome trapping.
- Achieved significant tumor regression and chemotherapy sensitization in NSCLC models.
- Demonstrated a favorable IC50 of 20 nmol/kg siRNA for in vivo gene knockdown.
Conclusions:
- RNA nanotechnology-based exosome delivery is a promising strategy for NSCLC treatment.
- Targeted delivery of siRNA using engineered exosomes can overcome delivery barriers and enhance therapeutic outcomes.
- This approach holds potential for improving patient outcomes in NSCLC by overcoming drug resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15Experimental RNAi